Regulatory News:

Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the « Company »), announces today that its annual financial report for the financial year ended December 31, 2021 has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers).

The Company's annual financial report includes:

- the management report; - the report on corporate governance; - the annual financial statements; - the statutory auditors’ reports.

It can be consulted on the Company’s website at www.aelisfarma.com.

***

About AELIS FARMA

Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). These new molecules hold great potential in the treatment of many brain diseases. CB1-SSi were developed by Aelis Farma on the basis of the discovery of a new natural defense mechanism of the brain made by the team of Dr. Pier Vincenzo Piazza, CEO of the Company, when he was Director of the Inserm Magendie Neurocentre in Bordeaux. For these discoveries, Dr. Piazza was awarded the Grand Prix of Inserm, and the Grand Prix of Neurology of the French Academy of Sciences, which are among the most prestigious French awards for medicine and neurology.

Aelis Farma is developing two first-in-class drug candidates that are at the clinical stage, AEF0117 and AEF0217, and has a portfolio of innovative CB1-SSi for the treatment of other diseases associated with dysregulation of CB1 receptor activity.

AEF0117, which targets the disorders due to excessive cannabis use (addiction and psychosis), has demonstrated efficacy in a phase 2a clinical trial and will enter a phase 2b clinical trial in the United States in 2022. Aelis Farma has an exclusive option license agreement with Indivior PLC, a leading pharmaceutical company in the treatment of addiction, for the development and commercialization of AEF0117 for disorders due to excessive cannabis use. As part of this agreement, Aelis Farma received $30 million (option payment). If Indivior exercises the license option at the end of the phase 2b, Aelis Farma will receive a $100 million license fee (potentially in 2024) and up to $340 million in additional payments contingent on the achievement of development, regulatory and commercial milestones, as well as royalties on net sales of AEF0117 ranging between 12% and 20%.

AEF0217, which targets various cognitive disorders including those associated with Down syndrome, is progressing successfully in its phase 1/2 program and could provide the first proof of efficacy in early 2023. This compound has undergone an extensive preclinical proof-of-concept program using highly innovative and highly predictive tests to assess cognitive functions. In this context, AEF0217 has demonstrated its ability to completely reverse deficits in several models of cognitive disorders such as Down syndrome and Fragile X syndrome, as well as in models of certain cognitive deficits associated with aging.

Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.

For more information: www.aelisfarma.com

ISIN: FR0014007ZB4 Ticker: AELIS B Compartment of Euronext Paris

AELIS FARMA Pier Vincenzo Piazza Co-founder and CEO contact@aelisfarma.com

NewCap Dusan Oresansky/Marine de Fages Investor Relations aelis@newcap.eu +33 1 44 71 94 92

NewCap Nicolas Merigeau Media Relations nmerigeau@newcap.fr +33 1 44 71 94 98

Aelis Farma (EU:AELIS)
Historical Stock Chart
Von Okt 2022 bis Nov 2022 Click Here for more Aelis Farma Charts.
Aelis Farma (EU:AELIS)
Historical Stock Chart
Von Nov 2021 bis Nov 2022 Click Here for more Aelis Farma Charts.